secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0001213900-24-102134
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma receives Nasdaq deficiency notices for low equity and low bid price
--------------------------------------------------------------------------------

- Stockholders' equity of $746,286 as of Sep 30, 2024, below Nasdaq's $2.5M minimum.
- Has until Jan 3, 2025 to submit a compliance plan; Nasdaq may grant up to 180-day extension.
- Separate bid price deficiency: common stock below $1.00 for 30 consecutive business days; cure period until May 19, 2025.
- Both deficiencies have no immediate effect on listing, but failure to regain compliance could lead to delisting.
- Company evaluating options to regain compliance; no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024102134/0001213900-24-102134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024102134/ea0222513-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-102134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer